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Stroke is the leading cause of adult disability in the United States. Because post-stroke
inflammation is a critical determinant of damage and recovery after stroke, understanding
the interplay between the immune system and the brain after stroke holds much promise
for therapeutic intervention. An understudied, but important aspect of this interplay is the
role of meninges that surround the brain. All blood vessels travel through the meningeal
space before entering the brain parenchyma, making the meninges ideally located to act
as an immune gatekeeper for the underlying parenchyma. Emerging evidence suggests
that the actions of immune cells resident in the meninges are essential for executing this
gatekeeper function. Mast cells (MCs), best known as proinflammatory effector cells,
are one of the long-term resident immune cells in the meninges. Here, we discuss
recent findings in the literature regarding the role of MCs located in the meningeal space
and stroke pathology. We review the latest advances in mouse models to investigate
the roles of MCs and MC-derived products in vivo, and the importance of using these
mouse models. We examine the concept of the meninges playing a critical role in brain
and immune interactions, reevaluate the perspectives on the key effectors of stroke
pathology, and discuss the opportunities and challenges for therapeutic development.
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INTRODUCTION
Every year, ∼800,000 people suffer from stroke in the United States (Benjamin et al., 2018).
The currently available therapies for acute stroke focus on removal of the blood clot, either
pharmacologically or mechanically (Fisher and Saver, 2015). With advances in careful patient
selection for these therapies, the time window for therapy initiation can be extended up to 24 h
(Albers et al., 2018; Nogueira et al., 2018). However, the majority of patients are still not eligible
for these therapies. Ischemic stroke occurs when the blood supply to the brain is interrupted by
a blood clot. This initiates a cascade of events that includes excitotoxicity, free radical release,
mitochondrial changes, and various degrees of immune response that leads to neuronal and glial
cell death, blood-brain barrier dysfunction and ultimately the clinical symptoms (Moskowitz et al.,
2010; Knowland et al., 2014; George and Steinberg, 2015). The timing of these events differ, and
additionally, the post-stroke immune response has different phases that can be detrimental or
beneficial (Anrather and Iadecola, 2016). Thus, a detailed understanding of the post-stroke immune
response is necessary in order to better utilize its therapeutic potential.
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The brain is long considered to be an immune-privileged
organ (Louveau et al., 2015a). This is in part due to its anatomical
isolation from the rest of the body, having its own unique
resident immune cells (microglia), and having restricted access
for circulating immune cells under homeostatic conditions.
This is important for homeostatic functions but becomes
especially important in pathological conditions. More recently,
meninges—the membranes surrounding the brain—have been
proposed to play important roles in the regulation of brain-
immune interactions (Rua and McGavern, 2018). Emerging
evidence suggests that the actions of immune cells resident in the
meninges are important for the immunoregulatory role of the
meninges (Rua and McGavern, 2018). Mast cells (MCs) reside
in high numbers within the meninges. These tissue-resident
immune cells have proinflammatory and immunoregulatory
roles (Grimbaldeston et al., 2007; Biggs et al., 2010; Galli et al.,
2011; Tsai et al., 2011), and play key functions in both innate
and adaptive immune responses. They act as constitutive or
inducible sources of many cytokines, chemokines and proteases
(Mukai et al., 2018). This makes them potential targets for
therapeutic intervention, depending on their roles in the
pathophysiology. Fortunately, there are several methodologies
to study the role of MCs and MC-derived products in vivo
(Galli et al., 2015).
Here, we discuss the evidence that MCs located
in the meningeal space can worsen stroke pathology.
We also review some of the latest advances in mouse
models to investigate the roles of MCs and MC-derived
products in vivo, and the importance of using these
mouse models. We examine the concept of the meninges
playing a critical role in brain and immune interactions,
reevaluate perspectives on key effectors of stroke
pathology, and discuss the opportunities and challenges for
therapeutic development.
MENINGES AS KEY SITES FOR BRAIN
IMMUNE ACCESS
Meninges are the connective tissue that surrounds the brain
and spinal cord. They consist of three layers (Figure 1):
an outer thick layer, dura mater, that is attached to the
skull, an inner thin layer, pia mater, that is attached to
the brain and spinal cord parenchyma, and a spider net-like
structure, arachnoid mater, in between the dura and pia
maters. The blood vessels and the cerebrospinal fluid exist
within the space between the arachnoid mater and pia
mater (subarachnoid space). The meninges have long been
considered as just an anatomical barrier; however, accumulating
evidence suggests that they are important for brain–immune
communications in health and disease (Androdias et al., 2010;
Derecki et al., 2010; Shechter et al., 2013; Kwong et al.,
2017; Benakis et al., 2018). All the arteries that penetrate
the brain parenchyma first travel through the subarachnoid
space before entering into the brain. The venous blood
then travels along the sinuses within the dura mater before
exiting the skull. Moreover, the recent discovery of the
central nervous system (CNS)’s lymphatic vessels within the
meninges highlights their potential role in brain–immune
interactions (Aspelund et al., 2015; Louveau et al., 2015b). These
meningeal lymphatics have been shown to be important in
controlling both neuroinflammatory events and immune cell
trafficking (Louveau et al., 2018b). Additionally, direct vascular
channels that traverse the meninges have been discovered
recently between the bone marrow in the skull and the
FIGURE 1 | (A) Scheme shows how the brain is enveloped by the meninges that contain Mast cells (MCs) in both the dura mater and pia mater. (B) Before entering
the brain parenchyma, blood vessels course on the surface of the brain between the dura mater and pia mater. Therefore, as a resident immune cell in the meninges,
the MC has the potential to influence blood vessels and to function as a gatekeeper to influence brain inflammation and pathology. Reprinted from Arac et al. (2014)
with permission from Elsevier.
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brain surface (Herisson et al., 2018). These direct vascular
channels help enable myeloid cell migration into the brain
parenchyma in stroke (Herisson et al., 2018). All these vascular
structures (the arteries and veins, meningeal lymphatic vessels,
and direct vascular channels) travel through the meninges,
making the meninges ideal for a possible gatekeeper role
(Rua and McGavern, 2018).
While some immune cells locate to dura mater after
stroke (Benakis et al., 2018) or aseptic inflammation (Kwong
et al., 2017), there are also tissue-resident immune cells
normally residing in the meninges. One such immune cell
type is the MC (Dimlich et al., 1991; Arac et al., 2014;
Figure 1). MCs are tissue-resident immune cells. Mature
MCs do not circulate in the blood but exist especially in
tissues exposed to the exterior, such as skin, lungs, and
gut (Galli et al., 2011; Tsai et al., 2011). These regions
are generally critical for host defense and require strong
immune regulation, as they represent the interface between
the body and the external environment (Galli et al., 2008).
In this respect, it is not surprising that MCs exist at high
numbers in meninges as the meninges separate blood and an
immune-privileged brain parenchyma (Louveau et al., 2015a).
Given the meninges’ potential gatekeeper role in orchestrating
brain–immune interactions, meningeal MCs can play significant
roles in such interactions.
CELLULAR ELEMENTS OF POST-STROKE
INFLAMMATION
Inflammation is critically important in stroke pathology. Several
elements of the immune system play roles at different time points
after stroke. The first immune cells to respond to interruption
of blood flow to the brain are the resident microglia. There
is evidence that microglia show signs of activation within
30 min to 1 h after stroke (Ito et al., 2001; Clausen et al.,
2008); these changes evolve during the 12 h following stroke
and result in decreased microglial numbers within 24 h (Ito
et al., 2001). These changes persist several weeks after stroke
onset (Lambertsen et al., 2005; Perego et al., 2011). The
microglia secrete several pro- and anti-inflammatory cytokines
and chemokines (Clausen et al., 2008; Lambertsen et al., 2009),
and can be either detrimental (Neher et al., 2013) or beneficial
(Lambertsen et al., 2009; Neumann et al., 2009) through secreted
factors or direct phagocytosis.
One of the first immune cells that infiltrate the brain after
stroke is the neutrophil. They start infiltrating around 6 h after
stroke onset and reach peak numbers at 24 h (Perez-de-Puig
et al., 2015). The predominant effect of neutrophils appears to
be increased ischemic injury as inhibition of their trafficking
results in better outcomes (Allen et al., 2012; Jickling et al., 2015;
Neumann et al., 2015). However, there is also evidence that
neutrophils play role in resolution of inflammation (Cuartero
et al., 2013) and promotion of remodeling (Christoffersson
et al., 2012) after stroke. Thus, the role of neutrophils in stroke
pathology is more complex, which may in part account for the
failure of translational approaches targeting neutrophils as stroke
therapy (Jickling et al., 2015).
Monocytes follow neutrophils in parenchymal infiltration
after a stroke, starting to infiltrate around 6–48 h after stroke
onset and staying in the brain weeks thereafter (Lambertsen
et al., 2005; Perego et al., 2011). The CCR2+Ly6Chigh
monocytes/macrophages are thought to be involved with
the acute inflammation, thus worsening the damage, whereas
CX3CR1+Ly6Clow macrophages are considered as the immune
cells involved in the repair process (Garcia-Bonilla et al., 2016;
Tsuyama et al., 2018). However, monocyte response after stroke
is very complicated. For example, the so-called inflammatory
CCR2+Ly6Chigh monocytes enter first, then are converted to
regulatory CX3CR1+Ly6Clow macrophages (Garcia-Bonilla
et al., 2016). Interestingly, efforts to target these monocytes
populations have shown mixed results; reducing monocyte
infiltration reduced stroke recovery in one study (Wattananit
et al., 2016), while another study concluded that targeting
monocyte subsets did not change the outcome after stroke
(Schmidt et al., 2017).
The response of lymphocytes (T and B cells) after stroke
is quite different from that of the other immune cells as they
tend to infiltrate the brain at later time points (days) and
stay longer (weeks to months) after stroke onset (Liesz et al.,
2013a). The role of these cells depends on the subtype of
lymphocytes involved, for example, T cells can worsen the
injury (Yilmaz et al., 2006; Clarkson et al., 2014; Mracsko
et al., 2014). More specifically, regulatory T cells have been
shown to be protective via secretion of interleukin-10 (Liesz
et al., 2009, 2013b), whereas gamma-delta-T cells can worsen
the injury by secreting interleukin-17 (Shichita et al., 2009).
Moreover, targeting T cell infiltration by inhibiting their
trafficking into the brain parenchyma protected the brain
against deleterious neuroinflammation (Liesz et al., 2011b).
However, amplifying regulatory T cells with a CD28 superagonist
in preclinical studies have elicited conflicting outcomes, and
resulted in reduced brain damage in one study (Na et al.,
2015), vs. increased brain damage in another (Schuhmann et al.,
2015). Moreover, treatment with another immunomodulatory
drug, FTY720, despite reducing the post-stroke lymphocyte
infiltration after stroke did not improve the post-stroke
outcomes (Liesz et al., 2011a). The role of B cells in stroke
pathology is also very unclear. Although in some studies B
cells did not have any direct effect on the stroke pathology
(Yilmaz et al., 2006; Schuhmann et al., 2017), in others they
were shown to be beneficial (Ren et al., 2011; Chen et al.,
2012). However, B cells were also shown to have delayed
deleterious effects such as cognitive impairment after stroke
(Doyle et al., 2015).
MCs have been proposed to play important roles in stroke
pathology. Specifically, cerebral MCs were shown to worsen
the brain swelling and neutrophil accumulation after stroke
(Strbian et al., 2006) and stroke induced the degranulation of
brain parenchymal MCs (Biran et al., 2008; Jin et al., 2009;
Lindsberg et al., 2010). Moreover, a MC stabilizer in rats,
cromolyn, was shown to be protective in stroke (Strbian et al.,
2007; Jin et al., 2009). Cerebral MCs were also shown to
mediate blood-brain barrier disruption after stroke (Mattila et al.,
2011; McKittrick et al., 2015). As opposed to these studies,
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which proposed a role for cerebral MCs in worsening stroke
pathology, another study (reviewed in detail below), proposed
that meningeal, rather than cerebral, MCs play important roles
in exacerbating stroke pathology, in part by secreting IL-6
(Arac et al., 2014).
Overall, despite being a major participant in stroke pathology,
inflammatory responses after stroke are complex, and attempts
should be made to understand their detailed pathophysiological
mechanisms before attempting therapeutic interventions.
In vivo MODELS TO STUDY MC
FUNCTION (“MC KNOCK-IN MICE”)
MCs are tissue-resident immune cells derived from bone
marrow. Small numbers of MC progenitors exist in the blood,
but they complete their differentiation and maturation in tissue
microenvironments (Galli et al., 2008, 2011). MCs can be
activated by diverse mechanisms including via binding of antigen
to antigen-specific IgE (Galli and Tsai, 2012), as well as by
physical agents, innate danger signals (Supajatura et al., 2002),
venoms (Metz et al., 2006), complement activation (Schäfer
et al., 2013), and exposure to certain chemokines and cytokines.
Upon activation, MCs can secrete either stored mediators (such
as histamine and heparin) or de novo synthesized cytokines,
chemokines, and growth factors (Mukai et al., 2018). These
MC-derived products have been shown to have positive or
negative effects on inflammation (Galli et al., 2008). However,
many of these MC-derived products are also produced by a
variety of other immune cells.
In order to identify a role for MCs in different biological
settings, one can ablate MCs selectively (either by a drug
or antibody, or genetically) to support their necessity, and
then replace their function selectively to support claims of
sufficiency. Pharmacological approaches such as MC stabilizers
(cromolyn) or activators (c48/80) have commonly been used to
infer a role for MCs. However, both of these drugs can have
MC-independent effects on other immune cells (Arumugam
et al., 2006; Oka et al., 2012; Schemann et al., 2012). There are
also other approaches using recombinant MC proteases, such as
tryptase, chymase, and tyrosine kinase inhibitors. However, all
of these approaches have potential off-target effects limiting the
interpretation of the results (Galli et al., 2015).
As these approaches lack true specificity for MCs, genetic
approaches represent a more definitive way to assess the
functions of MCs in vivo. Two commonly used genetically
MC-deficient mice are theKitW/W-v andKitW-sh/W-sh mice. These
mice have different types of mutations affecting the c-kit gene
that result in a profound deficiency of MCs and melanocytes
in both mice. However, both WBB6F1-KitW/W-v and C57BL/6-
KitW-sh/W-sh also have several other abnormalities within and
outside the immune system, including effects on hematopoietic
cells other than MCs (Galli et al., 2015). Thus, the differences in
the biological responses in these KitW/W-v and KitW-sh/W-sh mice
compared with wild type (WT)micemay, in principle, reflect any
of the abnormalities in these mice and are not necessarily due to
their MC deficiency. However, the MC deficiency in these mice
can be selectively ‘‘repaired’’ by the adoptive transfer of in vitro-
derived WT or mutant MCs (Nakano et al., 1985; Galli et al.,
2005; Grimbaldeston et al., 2005). These in vitro-grown, bone
marrow-derived, cultured MCs (BMCMCs) can be administered
systemically or locally to create the so-called ‘‘MC knock-in
mice’’ (Galli et al., 2015). These engrafted BMCMCs were shown
to survive, and function normally, up to 18 weeks in lungs (Yu
et al., 2006), 12 weeks in the skin (Biggs et al., 2010), and 10 weeks
in the meninges (Arac et al., 2014). Moreover, the numbers of
MCs in the MC knock-in mice are generally equivalent to those
of the WT animals (Yu et al., 2006; Biggs et al., 2010; Arac et al.,
2014). MC knock-in mice have been widely used to assess the
roles of MCs in several biological events in vivo.
Despite the power of MC knock-in mice, these mice still carry
potential problems inherent to c-kit related abnormalities (and
other abnormalities in the KitW-sh/W-sh mice) in the mutant mice.
To overcome this issue, MC-deficient mice with normal c-kit
function were developed by using MC-specific Cre recombinase
approach (Dudeck et al., 2011; Feyerabend et al., 2011; Lilla
et al., 2011). Such mice profoundly lack MCs (and to a lesser
extent, basophils), but have normal c-kit function and lack the
known abnormalities that the c-kitmutant mice have. Moreover,
inducible models of MC deficiency were also developed by using
the MC-specific Cre recombinase and inducible diphtheria toxin
receptor expression (Dudeck et al., 2011; Otsuka et al., 2011;
Reber et al., 2014). Injection of diphtheria toxin locally to the
site of interest results in profound depletion of local MCs in
these mice.
Given all these in vivo models to study MC function (with
different pros and cons), one recommended approach has been
to use more than one of these models to assess the initial
biological responses, and if there are consistent results between
the models, then proceeding to further studies (Galli et al.,
2015). For additional discussion of these models, we recommend
reading this review (Galli et al., 2015).
MENINGEAL MCs EXACERBATE STROKE
PATHOLOGY
We utilized some of these various in vivo models in order to
assess the role of MCs in stroke pathology (Arac et al., 2014).
WBB6F1-KitW/W-v mice had significantly smaller infarcts and
less brain swelling compared to WT controls at 3 and 14 days
after stroke. Systemic engraftment of WT MCs in these c-kit
mutant mice resulted in the same extent of injury as the WT
mice. In parallel to these results, the MC-deficient Cpa3-Cre;
Mc1–1fl/fl mice (Lilla et al., 2011; MC-deficient mice with normal
c-kit function) also had a smaller extent of stroke pathology
when compared to their corresponding WT counterparts. Both
mouse models also showed a similar MC-dependent pattern for
myeloid, but not lymphoid, cell numbers in the brain at 3 days
after stroke. Together, these data from two different types of
in vivo mouse models of genetically-determined MC deficiency
provide strong support that MCs play an important role in
worsening the brain injury after stroke.
Because the MC deficiencies in both of these models are
in all examined tissues, it is hard to discern which population
of MCs might be critical for this effect. Thus, we compared
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FIGURE 2 | Location of MCs in the central nervous system (CNS). Representative toluidine blue-stained images of and quantification of MCs in dura mater (A), pia
mater (B), and brain parenchyma (C) of MC-deficient WBB6F1-KitW/W-v mice and the corresponding wild type (WT) mice and MC-engrafted KitW/W-v mice. MCs
stain purple with toluidine blue; arrows indicate representative MCs. Insets show magnified images of MCs in each tissue. Data are expressed as means+SEM. The
number of mice in each group is indicated in (or over) each bar. ∗P < 0.05. Scale bars: 100 mm (A–C). Reprinted from Arac et al. (2014) with permission from
Elsevier.
the number of CNS MCs in the MC-engrafted WBB6F1-
KitW/W-v mice to those of WT (WBB6F1-Kit+/+) mice. Both
WT mice and MC-engrafted mice had similar numbers of MCs
in the dura and pia mater both before and 2 weeks after
stroke (Figures 2A,B). In contrast, the brain parenchyma of
the MC-engrafted mice had either no or substantially fewer
MCs (Figure 2C). These data strongly suggest that brain
parenchymal MCs are not responsible for the MC-dependent
worsening of the stroke pathology observed in this mouse
model. It instead suggests a potential role for meningeal
MCs in modulating this response. Moreover, the density of
MCs in the dura mater of both WT and MC-engrafted mice
(15–27 cells/mm2) is similar to that in humans (Varatharaj
et al., 2012; 11–23 cells/mm2). In order to calculate these dural
MC densities, we used dura mater whole mount preparations
(Figure 2A). This whole mount preparation of dura mater
was also later used to identify the meningeal lymphatics
(Louveau et al., 2015b, 2018a).
To test whether the meningeal MCs are sufficient in
modulating the MC-dependent stroke pathology, we engrafted
BMCMCs locally into themeninges.With amodified intracranial
injection method, the MCs engraft only in the meninges and
the number of meningeal MCs in MC-engrafted animals are
similar to those of the WT mice (Sayed et al., 2010; Arac et al.,
2014). After meningeal engraftment of MCs, MC-engrafted
mice developed significantly worse injury after stroke (Arac
et al., 2014). This provides strong evidence that the meningeal
MCs are sufficient to elicit the MC-dependent effects in
stroke pathology. Moreover, we found by microarray analysis
of the dura of MC-deficient WBB6F1-KitW/W-v mice, the
corresponding WT (WBB6F1-Kit+/+) mice, and WBB6F1-
KitW/W-v mice which had been engrafted in the meninges
with WT BMCMCs (unpublished data), that the meninges
are a site of inflammation-related activity after stroke and
that the meningeal inflammatory gene response to stroke
is modulated, at least in part, by MCs (Figure 3A). We
found that many stroke-activated genes in the meninges are
involved in the regulation of inflammatory and immune
system processes. These include cytokines, chemokines,
cell adhesion molecules, immune signaling receptors and
extracellular matrix remodeling molecules, all of which are
known to contribute to leukocyte migration and activation
(Figure 3B). Notably, we found that many of the stroke-
induced gene changes involved in inflammation were either
absent or exhibited a smaller response in MC-deficient
mice, but were recapitulated when MCs were engrafted
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FIGURE 3 | Meningeal gene expression changes after stroke. (A) Heatmap showing the fold-change in expression of genes significantly changed (p < 0.05) after
stroke in WT (WBB6F1-Kit+/+) mice with the corresponding change in expression in MC-deficient (WBB6F1-KitW/W-v) and MC-engrafted [WBB6F1-KitW/W-v mice
which had been engrafted in the meninges with WT bone marrow-derived, cultured MCs (BMCMCs)] mice (irrespective of whether the gene changes in these two
groups after stroke reach significance). The genes represented are those with an absolute fold-change after stroke of ≥1.5 in WT mice. (B) Pathway map of the
functional grouping of genes that were significantly upregulated after stroke in WT mice. (C) Dot plots showing the log2 fold-change in expression after stroke of
genes within the indicated gene ontology groups in each of three mouse groups. The genes represented in each gene ontology group were significantly upregulated
after stroke in WT mice, with a fold-change of ≥1.5. Each data point within a mouse group represents a different gene. Red line indicates median. ∗p < 0.05;
#p = 0.05.
into these mice, consistent with the idea that MCs can
modulate the meningeal inflammatory gene changes after
stroke (Figure 3C).
In order to identify the MC-derived products that influence
stroke pathology, BMCMCs derived from two candidate factor-
deficient mice (IL-6 and CCL7) were injected into the meninges
of MC-deficient mice (Arac et al., 2014). We found that
mice meningeally engrafted with BMCMCs which lack IL-6
failed to demonstrate MC-dependent responses in stroke
pathology compared to the WT BMCMC engrafted mice. By
contrast, MC-derived CCL7 had less of an effect on stroke
pathology (Arac et al., 2014). This demonstrates how meningeal
MC-derived IL-6 can, in part, explain the MC-dependent effects
in stroke pathology.
There are several questions that require further studies.
For example, how does the meningeal MC-derived IL-6
execute its function to exacerbate stroke pathology? What
downstream pathways are involved in this biological response?
Does it alter the meningeal access of immune cells to the
brain? What are its effects on brain meningeal lymphatics?
Likewise, what are the mechanisms involved in stimulating the
meningeal MCs to release IL-6 after a stroke? Are there other
MC-derived factors that also might be involved in worsening
the stroke pathology? Contrary to these, could anti-coagulative
effects of MC-derived heparin proteoglycan and/or proteases
have effects in dissolving the blood clot in ischemic stroke?
Moreover, there could also be other, yet to be identified,
meningeal MC-derived products that are important in the
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repair process after stroke. Thus, one should be cautious
in directly targeting MCs as a therapeutic for stroke (Ocak
et al., 2018). These and many other questions need to be
investigated to better understand the role of meningeal MCs in
stroke pathology.
OPPORTUNITIES AND CHALLENGES FOR
FUTURE
Immune responses after stroke are complex with many
elements involved, and it is not the focus of this article to
comprehensively review that literature; interested readers can
find up-to-date review articles on this topic (McCombe and
Read, 2008; Iadecola and Anrather, 2011; Macrez et al., 2011;
Lambertsen et al., 2018; Rayasam et al., 2018). The post-stroke
immune response potentially holds very promising targets
for therapeutic interventions for stroke (Arac et al., 2011;
Macrez et al., 2011). However, these post-stroke immune events
have not been well characterized, with many of the immune
responses potentially having dual roles. Development of new
and effective therapeutics for stroke will require detailed,
mechanistic studies before consideration of specific approaches
for therapeutic intervention. Here, we have discussed recent
advances in post-stroke immune response with a particular
focus on the role of meningeal MCs. Given the increasing
importance and key roles of meninges in the regulation
of brain–immune interactions (Rua and McGavern, 2018),
meningeal MCs are ideally located to play potentially key roles
in these interactions. As MCs have diverse roles in many
immune responses (Galli et al., 2005, 2008), their key location
in the meninges makes them potentially important players in
the regulation of immune responses in the brain during health
and disease.
Identifying the roles of several immune elements in stroke
pathology is critical for the development of effective therapeutics.
Fortunately, there are many advanced immunological tools
to perform mechanistic studies. Without such detailed
characterization of post-stroke immune responses, performing
clinical tests of potential targets will likely result in failures, and
may decrease the enthusiasm for future studies.
DATA AVAILABILITY
The datasets generated for this study are available on request to
the corresponding author.
AUTHOR CONTRIBUTIONS
AA wrote the initial draft of the review. All authors contributed
to revising the manuscript, reading and approving the
submitted version.
FUNDING
This work was supported in part by Stanford School of Medicine
Dean’s Fellowship (Neizer Funds; AA); National Institutes
of Health (NIH) grants NS065723 (AA), NS109315 (AA),
NS080062 and NS37520-08 (GS) and AI070813, AI023990, and
CA072074 (SG); Russell and Elizabeth Siegelman (GS); Bernard
and Ronni Lacroute (GS); William Randolph Hearst Foundation
(GS); an Australian NHMRC Career Development Fellowship
and NHMRC project grants (MG).
ACKNOWLEDGMENTS
We thank Christine Plant for assistance with the manuscript.
REFERENCES
Albers, G. W., Marks, M. P., Kemp, S., Christensen, S., Tsai, J. P., Ortega-
Gutierrez, S., et al. (2018). Thrombectomy for stroke at 6 to 16 hours
with selection by perfusion imaging. N. Engl. J. Med. 378, 708–718.
doi: 10.1056/NEJMoa1713973
Allen, C., Thornton, P., Denes, A., McColl, B. W., Pierozynski, A., Monestier, M.,
et al. (2012). Neutrophil cerebrovascular transmigration triggers rapid
neurotoxicity through release of proteases associated with decondensed DNA.
J. Immunol. 189, 381–392. doi: 10.4049/jimmunol.1200409
Androdias, G., Reynolds, R., Chanal, M., Ritleng, C., Confavreux, C., and Nataf, S.
(2010). Meningeal T cells associate with diffuse axonal loss in multiple sclerosis
spinal cords. Ann. Neurol. 68, 465–476. doi: 10.1002/ana.22054
Anrather, J., and Iadecola, C. (2016). Inflammation and stroke: an overview.
Neurotherapeutics 13, 661–670. doi: 10.1007/s13311-016-0483-x
Arac, A., Brownell, S. E., Rothbard, J. B., Chen, C., Ko, R. M., Pereira, M. P., et al.
(2011). Systemic augmentation of αB-crystallin provides therapeutic benefit
twelve hours post-stroke onset via immune modulation. Proc. Natl. Acad. Sci.
U S A 108, 13287–13292. doi: 10.1073/pnas.1107368108
Arac, A., Grimbaldeston, M. A., Nepomuceno, A. R., Olayiwola, O., Pereira, M. P.,
Nishiyama, Y., et al. (2014). Evidence that meningeal mast cells can worsen
stroke pathology in mice. Am. J. Pathol. 184, 2493–2504. doi: 10.1016/j.ajpath.
2014.06.003
Arumugam, T., Ramachandran, V., and Logsdon, C. D. (2006). Effect of cromolyn
on S100P interactions with RAGE and pancreatic cancer growth and invasion
in mouse models. J. Natl. Cancer Inst. 98, 1806–1818. doi: 10.1093/jnci/djj498
Aspelund, A., Antila, S., Proulx, S. T., Karlsen, T. V., Karaman, S., Detmar, M.,
et al. (2015). A dural lymphatic vascular system that drains brain interstitial
fluid and macromolecules. J. Exp. Med. 212, 991–999. doi: 10.1084/jem.201
42290
Benakis, C., Llovera, G., and Liesz, A. (2018). The meningeal and choroidal
infiltration routes for leukocytes in stroke. Ther. Adv. Neurol. Disord.
11:1756286418783708. doi: 10.1177/1756286418783708
Benjamin, E. J., Virani, S. S., Callaway, C. W., Chamberlain, A. M., Chang, A. R.,
Cheng, S., et al. (2018). Heart disease and stroke statistics-2018 update:
a report from the american heart association. Circulation 137, e67–e492.
doi: 10.1161/CIR.0000000000000558
Biggs, L., Yu, C., Fedoric, B., Lopez, A. F., Galli, S. J., and Grimbaldeston, M. A.
(2010). Evidence that vitamin D(3) promotes mast cell-dependent reduction
of chronic UVB-induced skin pathology in mice. J. Exp. Med. 207, 455–463.
doi: 10.1084/jem.20091725
Biran, V., Cochois, V., Karroubi, A., Arrang, J. M., Charriaut-Marlangue, C.,
and Heron, A. (2008). Stroke induces histamine accumulation and mast cell
degranulation in the neonatal rat brain. Brain Pathol. 18, 1–9. doi: 10.1111/j.
1750-3639.2007.00092.x
Chen, Y., Bodhankar, S., Murphy, S. J., Vandenbark, A. A., Alkayed, N. J.,
and Offner, H. (2012). Intrastriatal B-cell administration limits infarct
size after stroke in B-cell deficient mice. Metab. Brain Dis. 27, 487–493.
doi: 10.1007/s11011-012-9317-7
Christoffersson, G., Vågesjö, E., Vandooren, J., Liden, M., Massena, S.,
Reinert, R. B., et al. (2012). VEGF-A recruits a proangiogenic MMP-9-
delivering neutrophil subset that induces angiogenesis in transplanted
Frontiers in Cellular Neuroscience | www.frontiersin.org 7 April 2019 | Volume 13 | Article 126
Arac et al. Mast Cells and Stroke Pathology
hypoxic tissue. Blood 120, 4653–4662. doi: 10.1182/blood-2012-04-
421040
Clarkson, B. D., Ling, C., Shi, Y., Harris,M. G., Rayasam, A., Sun, D., et al. (2014). T
cell-derived interleukin (IL)-21 promotes brain injury following stroke in mice.
J. Exp. Med. 211, 595–604. doi: 10.1084/jem.20131377
Clausen, B. H., Lambertsen, K. L., Babcock, A. A., Holm, T. H., Dagnaes-
Hansen, F., and Finsen, B. (2008). Interleukin-1beta and tumor necrosis
factor-alpha are expressed by different subsets of microglia and macrophages
after ischemic stroke in mice. J. Neuroinflammation 5:46. doi: 10.1186/1742-
2094-5-46
Cuartero, M. I., Ballesteros, I., Moraga, A., Nombela, F., Vivancos, J.,
Hamilton, J. A., et al. (2013). N2 neutrophils, novel players in brain
inflammation after stroke: modulation by the PPARγ agonist rosiglitazone.
Stroke 44, 3498–3508. doi: 10.1161/strokeaha.113.002470
Derecki, N. C., Cardani, A. N., Yang, C. H., Quinnies, K. M., Crihfield, A.,
Lynch, K. R., et al. (2010). Regulation of learning and memory by meningeal
immunity: a key role for IL-4. J. Exp. Med. 207, 1067–1080. doi: 10.1084/jem.
20091419
Dimlich, R. V., Keller, J. T., Strauss, T. A., and Fritts, M. J. (1991). Linear arrays of
homogeneous mast cells in the dura mater of the rat. J. Neurocytol. 20, 485–503.
doi: 10.1007/bf01252276
Doyle, K. P., Quach, L. N., Sole,M., Axtell, R. C., Nguyen, T. V., Soler-Llavina, G. J.,
et al. (2015). B-lymphocyte-mediated delayed cognitive impairment following
stroke. J. Neurosci. 35, 2133–2145. doi: 10.1523/JNEUROSCI.4098-14.2015
Dudeck, A., Dudeck, J., Scholten, J., Petzold, A., Surianarayanan, S., Kohler, A.,
et al. (2011). Mast cells are key promoters of contact allergy that mediate
the adjuvant effects of haptens. Immunity 34, 973–984. doi: 10.1016/j.immuni.
2011.03.028
Feyerabend, T. B., Weiser, A., Tietz, A., Stassen, M., Harris, N., Kopf, M., et al.
(2011). Cre-mediated cell ablation contests mast cell contribution in models
of antibody- and T cell-mediated autoimmunity. Immunity 35, 832–844.
doi: 10.1016/j.immuni.2011.09.015
Fisher, M., and Saver, J. L. (2015). Future directions of acute ischaemic stroke
therapy. Lancet Neurol. 14, 758–767. doi: 10.1016/s1474-4422(15)00054-x
Galli, S. J., Borregaard, N., and Wynn, T. A. (2011). Phenotypic and functional
plasticity of cells of innate immunity: macrophages, mast cells and neutrophils.
Nat. Immunol. 12, 1035–1044. doi: 10.1038/ni.2109
Galli, S. J., Grimbaldeston, M., and Tsai, M. (2008). Immunomodulatory mast
cells: negative, as well as positive, regulators of immunity. Nat. Rev. Immunol.
8, 478–486. doi: 10.1038/nri2327
Galli, S. J., Kalesnikoff, J., Grimbaldeston, M. A., Piliponsky, A. M.,
Williams, C. M., and Tsai, M. (2005). Mast cells as ‘‘tunable’’ effector
and immunoregulatory cells: recent advances. Annu. Rev. Immunol. 23,
749–786. doi: 10.1146/annurev.immunol.21.120601.141025
Galli, S. J., and Tsai, M. (2012). IgE and mast cells in allergic disease. Nat. Med. 18,
693–704. doi: 10.1038/nm.2755
Galli, S. J., Tsai, M., Marichal, T., Tchougounova, E., Reber, L. L., and Pejler, G.
(2015). Approaches for analyzing the roles of mast cells and their proteases
in vivo. Adv. Immunol. 126, 45–127. doi: 10.1016/bs.ai.2014.11.002
Garcia-Bonilla, L., Faraco, G., Moore, J., Murphy, M., Racchumi, G., Srinivasan, J.,
et al. (2016). Spatio-temporal profile, phenotypic diversity and fate of
recruited monocytes into the post-ischemic brain. J. Neuroinflammation
13:285. doi: 10.1186/s12974-016-0750-0
George, P. M., and Steinberg, G. K. (2015). Novel stroke therapeutics: unraveling
stroke pathophysiology and its impact on clinical treatments. Neuron 87,
297–309. doi: 10.1016/j.neuron.2015.05.041
Grimbaldeston, M. A., Chen, C. C., Piliponsky, A. M., Tsai, M., Tam, S. Y., and
Galli, S. J. (2005). Mast cell-deficient W-sash c-kit mutant Kit W-sh/W-sh
mice as a model for investigating mast cell biology in vivo. Am. J. Pathol. 167,
835–848. doi: 10.1016/S0002-9440(10)62055-X
Grimbaldeston, M. A., Nakae, S., Kalesnikoff, J., Tsai, M., and Galli, S. J. (2007).
Mast cell-derived interleukin 10 limits skin pathology in contact dermatitis
and chronic irradiation with ultraviolet B. Nat. Immunol. 8, 1095–1104.
doi: 10.1038/ni1503
Herisson, F., Frodermann, V., Courties, G., Rohde, D., Sun, Y., Vandoorne, K.,
et al. (2018). Direct vascular channels connect skull bone marrow and the
brain surface enabling myeloid cell migration. Nat. Neurosci. 21, 1209–1217.
doi: 10.1038/s41593-018-0213-2
Iadecola, C., andAnrather, J. (2011). The immunology of stroke: frommechanisms
to translation. Nat. Med. 17, 796–808. doi: 10.1038/nm.2399
Ito, D., Tanaka, K., Suzuki, S., Dembo, T., and Fukuuchi, Y. (2001). Enhanced
expression of Iba1, ionized calcium-binding adapter molecule 1, after transient
focal cerebral ischemia in rat brain. Stroke 32, 1208–1215. doi: 10.1161/01.str.
32.5.1208
Jickling, G. C., Liu, D., Ander, B. P., Stamova, B., Zhan, X., and Sharp, F. R.
(2015). Targeting neutrophils in ischemic stroke: translational insights
from experimental studies. J. Cereb. Blood Flow Metab. 35, 888–901.
doi: 10.1038/jcbfm.2015.45
Jin, Y., Silverman, A. J., and Vannucci, S. J. (2009). Mast cells are early
responders after hypoxia-ischemia in immature rat brain. Stroke 40, 3107–3112.
doi: 10.1161/strokeaha.109.549691
Knowland, D., Arac, A., Sekiguchi, K. J., Hsu, M., Lutz, S. E., Perrino, J.,
et al. (2014). Stepwise recruitment of transcellular and paracellular pathways
underlies blood-brain barrier breakdown in stroke. Neuron 82, 603–617.
doi: 10.1016/j.neuron.2014.03.003
Kwong, B., Rua, R., Gao, Y., Flickinger, J. Jr., Wang, Y., Kruhlak, M. J., et al. (2017).
T-bet-dependent NKp46+ innate lymphoid cells regulate the onset of TH17-
induced neuroinflammation. Nat. Immunol. 18, 1117–1127. doi: 10.1038/
ni.3816
Lambertsen, K. L., Clausen, B. H., Babcock, A. A., Gregersen, R., Fenger, C.,
Nielsen, H. H., et al. (2009). Microglia protect neurons against ischemia
by synthesis of tumor necrosis factor. J. Neurosci. 29, 1319–1330.
doi: 10.1523/jneurosci.5505-08.2009
Lambertsen, K. L., Finsen, B., and Clausen, B. H. (2018). Post-
stroke inflammation-target or tool for therapy? Acta Neuropathol.
doi: 10.1007/s00401-018-1930-z [Epub ahead of print].
Lambertsen, K. L., Meldgaard,M., Ladeby, R., and Finsen, B. (2005). A quantitative
study of microglial-macrophage synthesis of tumor necrosis factor during acute
and late focal cerebral ischemia in mice. J. Cereb. Blood Flow Metab. 25,
119–135. doi: 10.1038/sj.jcbfm.9600014
Liesz, A., Karcher, S., and Veltkamp, R. (2013a). Spectratype analysis of clonal T
cell expansion in murine experimental stroke. J. Neuroimmunol. 257, 46–52.
doi: 10.1016/j.jneuroim.2013.01.013
Liesz, A., Zhou, W., Na, S. Y., Hammerling, G. J., Garbi, N., Karcher, S., et al.
(2013b). Boosting regulatory T cells limits neuroinflammation in permanent
cortical stroke. J. Neurosci. 33, 17350–17362. doi: 10.1523/jneurosci.4901-
12.2013
Liesz, A., Sun, L., Zhou, W., Schwarting, S., Mracsko, E., Zorn, M., et al.
(2011a). FTY720 reduces post-ischemic brain lymphocyte influx but does not
improve outcome in permanent murine cerebral ischemia. PLoS One 6:e21312.
doi: 10.1371/journal.pone.0021312
Liesz, A., Zhou, W., Mracsko, E., Karcher, S., Bauer, H., Schwarting, S.,
et al. (2011b). Inhibition of lymphocyte trafficking shields the brain
against deleterious neuroinflammation after stroke. Brain 134, 704–720.
doi: 10.1093/brain/awr008
Liesz, A., Suri-Payer, E., Veltkamp, C., Doerr, H., Sommer, C., Rivest, S., et al.
(2009). Regulatory T cells are key cerebroprotective immunomodulators in
acute experimental stroke. Nat. Med. 15, 192–199. doi: 10.1038/nm.1927
Lilla, J. N., Chen, C. C., Mukai, K., BenBarak, M. J., Franco, C. B., Kalesnikoff, J.,
et al. (2011). Reduced mast cell and basophil numbers and function in
Cpa3-Cre; Mcl-1fl/fl mice. Blood 118, 6930–6938. doi: 10.1182/blood-2011-03-
343962
Lindsberg, P. J., Strbian, D., and Karjalainen-Lindsberg, M. L. (2010). Mast cells
as early responders in the regulation of acute blood-brain barrier changes after
cerebral ischemia and hemorrhage. J. Cereb. Blood Flow Metab. 30, 689–702.
doi: 10.1038/jcbfm.2009.282
Louveau, A., Filiano, A. J., and Kipnis, J. (2018a). Meningeal whole mount
preparation and characterization of neural cells by flow cytometry. Curr.
Protoc. Immunol. 121:e50. doi: 10.1002/cpim.50
Louveau, A., Herz, J., Alme, M. N., Salvador, A. F., Dong, M. Q., Viar, K. E.,
et al. (2018b). CNS lymphatic drainage and neuroinflammation are
regulated by meningeal lymphatic vasculature. Nat. Neurosci. 21, 1380–1391.
doi: 10.1038/s41593-018-0227-9
Louveau, A., Harris, T. H., and Kipnis, J. (2015a). Revisiting the mechanisms of
CNS immune privilege. Trends Immunol. 36, 569–577. doi: 10.1016/j.it.2015.
08.006
Frontiers in Cellular Neuroscience | www.frontiersin.org 8 April 2019 | Volume 13 | Article 126
Arac et al. Mast Cells and Stroke Pathology
Louveau, A., Smirnov, I., Keyes, T. J., Eccles, J. D., Rouhani, S. J., Peske, J. D., et al.
(2015b). Structural and functional features of central nervous system lymphatic
vessels. Nature 523, 337–341. doi: 10.1038/nature14432
Macrez, R., Ali, C., Toutirais, O., Le Mauff, B., Defer, G., Dirnagl, U., et al.
(2011). Stroke and the immune system: from pathophysiology to new
therapeutic strategies. Lancet Neurol. 10, 471–480. doi: 10.1016/s1474-4422(11)
70066-7
Mattila, O. S., Strbian, D., Saksi, J., Pikkarainen, T. O., Rantanen, V.,
Tatlisumak, T., et al. (2011). Cerebral mast cells mediate blood-brain
barrier disruption in acute experimental ischemic stroke through perivascular
gelatinase activation. Stroke 42, 3600–3605. doi: 10.1161/strokeaha.111.
632224
McCombe, P. A., and Read, S. J. (2008). Immune and inflammatory responses to
stroke: good or bad? Int. J. Stroke 3, 254–265. doi: 10.1111/j.1747-4949.2008.
00222.x
McKittrick, C. M., Lawrence, C. E., and Carswell, H. V. (2015). Mast cells
promote blood brain barrier breakdown and neutrophil infiltration in a mouse
model of focal cerebral ischemia. J. Cereb. Blood Flow Metab. 35, 638–647.
doi: 10.1038/jcbfm.2014.239
Metz, M., Piliponsky, A. M., Chen, C. C., Lammel, V., Abrink, M., Pejler, G.,
et al. (2006). Mast cells can enhance resistance to snake and honeybee venoms.
Science 313, 526–530. doi: 10.1126/science.1128877
Moskowitz, M. A., Lo, E. H., and Iadecola, C. (2010). The science of stroke:
mechanisms in search of treatments. Neuron 67, 181–198. doi: 10.1016/j.
neuron.2010.07.002
Mracsko, E., Liesz, A., Stojanovic, A., Lou, W. P., Osswald, M., Zhou, W., et al.
(2014). Antigen dependently activated cluster of differentiation 8-positive T
cells cause perforin-mediated neurotoxicity in experimental stroke. J. Neurosci.
34, 16784–16795. doi: 10.1523/jneurosci.1867-14.2014
Mukai, K., Tsai, M., Saito, H., and Galli, S. J. (2018). Mast cells as sources
of cytokines, chemokines, and growth factors. Immunol. Rev. 282, 121–150.
doi: 10.1111/imr.12634
Na, S. Y., Mracsko, E., Liesz, A., Hunig, T., and Veltkamp, R. (2015). Amplification
of regulatory T cells using a CD28 superagonist reduces brain damage after
ischemic stroke in mice. Stroke 46, 212–220. doi: 10.1161/strokeaha.114.007756
Nakano, T., Sonoda, T., Hayashi, C., Yamatodani, A., Kanayama, Y.,
Yamamura, T., et al. (1985). Fate of bone marrow-derived cultured mast
cells after intracutaneous, intraperitoneal and intravenous transfer into
genetically mast cell-deficient W/Wv mice. Evidence that cultured mast cells
can give rise to both connective tissue type and mucosal mast cells. J. Exp. Med.
162, 1025–1043. doi: 10.1084/jem.162.3.1025
Neher, J. J., Emmrich, J. V., Fricker, M., Mander, P. K., Thery, C., and Brown, G. C.
(2013). Phagocytosis executes delayed neuronal death after focal brain
ischemia. Proc. Natl. Acad. Sci. U S A 110, E4098–E4107. doi: 10.1073/pnas.
1308679110
Neumann, H., Kotter, M. R., and Franklin, R. J. (2009). Debris clearance by
microglia: an essential link between degeneration and regeneration. Brain 132,
288–295. doi: 10.1093/brain/awn109
Neumann, J., Riek-Burchardt, M., Herz, J., Doeppner, T. R., König, R.,
Hütten, H., et al. (2015). Very-late-antigen-4 (VLA-4)-mediated brain invasion
by neutrophils leads to interactions with microglia, increased ischemic injury
and impaired behavior in experimental stroke.Acta Neuropathol. 129, 259–277.
doi: 10.1007/s00401-014-1355-2
Nogueira, R. G., Jadhav, A. P., Haussen, D. C., Bonafe, A., Budzik, R. F., Bhuva, P.,
et al. (2018). Thrombectomy 6 to 24 hours after stroke with amismatch between
deficit and infarct. N. Engl. J. Med. 378, 11–21. doi: 10.1056/NEJMoa1706442
Ocak, U., Ocak, P. E., Wang, A., Zhang, J. H., Boling, W., Wu, P.,
et al. (2018). Targeting mast cell as a neuroprotective strategy. Brain Inj.
doi: 10.1080/02699052.2018.1556807 [Epub ahead of print].
Oka, T., Kalesnikoff, J., Starkl, P., Tsai, M., and Galli, S. J. (2012). Evidence
questioning cromolyn’s effectiveness and selectivity as a ‘mast cell stabilizer’
in mice. Lab. Invest. 92, 1472–1482. doi: 10.1038/labinvest.2012.116
Otsuka, A., Kubo, M., Honda, T., Egawa, G., Nakajima, S., Tanizaki, H., et al.
(2011). Requirement of interaction between mast cells and skin dendritic cells
to establish contact hypersensitivity. PLoS One 6:e25538. doi: 10.1371/journal.
pone.0025538
Perego, C., Fumagalli, S., and De Simoni, M. G. (2011). Temporal pattern of
expression and colocalization of microglia/macrophage phenotype markers
following brain ischemic injury in mice. J. Neuroinflammation 8:174.
doi: 10.1186/1742-2094-8-174
Perez-de-Puig, I., Miró-Mur, F., Ferrer-Ferrer, M., Gelpi, E., Pedragosa, J.,
Justicia, C., et al. (2015). Neutrophil recruitment to the brain in mouse and
human ischemic stroke. Acta Neuropathol. 129, 239–257. doi: 10.1007/s00401-
014-1381-0
Rayasam, A., Hsu, M., Kijak, J. A., Kissel, L., Hernandez, G., Sandor, M., et al.
(2018). Immune responses in stroke: how the immune system contributes to
damage and healing after stroke and how this knowledge could be translated to
better cures? Immunology 154, 363–376. doi: 10.1111/imm.12918
Reber, L. L., Marichal, T., Sokolove, J., Starkl, P., Gaudenzio, N., Iwakura, Y.,
et al. (2014). Contribution of mast cell-derived interleukin-1β to uric acid
crystal-induced acute arthritis in mice. Arthritis Rheumatol. 66, 2881–2891.
doi: 10.1002/art.38747
Ren, X., Akiyoshi, K., Dziennis, S., Vandenbark, A. A., Herson, P. S.,
Hurn, P. D., et al. (2011). Regulatory B cells limit CNS inflammation and
neurologic deficits in murine experimental stroke. J. Neurosci. 31, 8556–8563.
doi: 10.1523/JNEUROSCI.1623-11.2011
Rua, R., and McGavern, D. B. (2018). Advances in meningeal immunity. Trends
Mol. Med. 24, 542–559. doi: 10.1016/j.molmed.2018.04.003
Sayed, B. A., Christy, A. L., Walker, M. E., and Brown, M. A. (2010). Meningeal
mast cells affect early T cell central nervous system infiltration and blood-brain
barrier integrity through TNF: a role for neutrophil recruitment? J. Immunol.
184, 6891–6900. doi: 10.4049/jimmunol.1000126
Schäfer, B., Piliponsky, A. M., Oka, T., Song, C. H., Gerard, N. P., Gerard, C.,
et al. (2013). Mast cell anaphylatoxin receptor expression can enhance
IgE-dependent skin inflammation in mice. J. Allergy Clin. Immunol. 131,
541.e9–548.e9. doi: 10.1016/j.jaci.2012.05.009
Schemann, M., Kugler, E. M., Buhner, S., Eastwood, C., Donovan, J., Jiang, W.,
et al. (2012). The mast cell degranulator compound 48/80 directly activates
neurons. PLoS One 7:e52104. doi: 10.1371/journal.pone.0052104
Schmidt, A., Strecker, J. K., Hucke, S., Bruckmann, N. M., Herold, M.,
Mack, M., et al. (2017). Targeting different monocyte/macrophage subsets
has no impact on outcome in experimental stroke. Stroke 48, 1061–1069.
doi: 10.1161/strokeaha.116.015577
Schuhmann, M. K., Kraft, P., Stoll, G., Lorenz, K., Meuth, S. G., Wiendl, H.,
et al. (2015). CD28 superagonist-mediated boost of regulatory T cells
increases thrombo-inflammation and ischemic neurodegeneration during the
acute phase of experimental stroke. J. Cereb. Blood Flow Metab. 35, 6–10.
doi: 10.1038/jcbfm.2014.175
Schuhmann, M. K., Langhauser, F., Kraft, P., and Kleinschnitz, C. (2017). B cells
do not have a major pathophysiologic role in acute ischemic stroke in mice.
J. Neuroinflammation 14:112. doi: 10.1186/s12974-017-0890-x
Shechter, R., London, A., and Schwartz, M. (2013). Orchestrated leukocyte
recruitment to immune-privileged sites: absolute barriers versus educational
gates. Nat. Rev. Immunol. 13, 206–218. doi: 10.1038/nri3391
Shichita, T., Sugiyama, Y., Ooboshi, H., Sugimori, H., Nakagawa, R., Takada, I.,
et al. (2009). Pivotal role of cerebral interleukin-17-producing γδT cells
in the delayed phase of ischemic brain injury. Nat. Med. 15, 946–950.
doi: 10.1038/nm.1999
Strbian, D., Karjalainen-Lindsberg, M. L., Kovanen, P. T., Tatlisumak, T., and
Lindsberg, P. J. (2007). Mast cell stabilization reduces hemorrhage formation
and mortality after administration of thrombolytics in experimental ischemic
stroke. Circulation 116, 411–418. doi: 10.1161/circulationaha.106.655423
Strbian, D., Karjalainen-Lindsberg, M. L., Tatlisumak, T., and Lindsberg, P. J.
(2006). Cerebral mast cells regulate early ischemic brain swelling and
neutrophil accumulation. J. Cereb. Blood Flow Metab. 26, 605–612.
doi: 10.1038/sj.jcbfm.9600228
Supajatura, V., Ushio, H., Nakao, A., Akira, S., Okumura, K., Ra, C., et al. (2002).
Differential responses of mast cell Toll-like receptors 2 and 4 in allergy and
innate immunity. J. Clin. Invest. 109, 1351–1359. doi: 10.1172/jci0214704
Tsai, M., Grimbaldeston, M., and Galli, S. J. (2011). Mast cells and
immunoregulation/immunomodulation. Adv. Exp. Med. Biol. 716, 186–211.
doi: 10.1007/978-1-4419-9533-9_11
Tsuyama, J., Nakamura, A., Ooboshi, H., Yoshimura, A., and Shichita, T.
(2018). Pivotal role of innate myeloid cells in cerebral post-ischemic sterile
inflammation. Semin. Immunopathol. 40, 523–538. doi: 10.1007/s00281-018-
0707-8
Frontiers in Cellular Neuroscience | www.frontiersin.org 9 April 2019 | Volume 13 | Article 126
Arac et al. Mast Cells and Stroke Pathology
Varatharaj, A., Mack, J., Davidson, J. R., Gutnikov, A., and Squier, W. (2012). Mast
cells in the human dura: effects of age and dural bleeding. Childs Nerv. Syst. 28,
541–545. doi: 10.1007/s00381-012-1699-7
Wattananit, S., Tornero, D., Graubardt, N., Memanishvili, T., Monni, E.,
Tatarishvili, J., et al. (2016). Monocyte-derived macrophages contribute
to spontaneous long-term functional recovery after stroke in
mice. J. Neurosci. 36, 4182–4195. doi: 10.1523/JNEUROSCI.4317-
15.2016
Yilmaz, G., Arumugam, T. V., Stokes, K. Y., and Granger, D. N. (2006). Role of T
lymphocytes and interferon-γ in ischemic stroke. Circulation 113, 2105–2112.
doi: 10.1161/circulationaha.105.593046
Yu, M., Tsai, M., Tam, S. Y., Jones, C., Zehnder, J., and Galli, S. J. (2006). Mast cells
can promote the development of multiple features of chronic asthma in mice.
J. Clin. Invest. 116, 1633–1641. doi: 10.1172/jci25702
Conflict of Interest Statement: GS is a consultant for Qool Therapeutics, Peter
Lazic US, Inc., and NeuroSave. MG is employed by Genentech Inc.
The remaining authors declare that the research was conducted in the absence of
any commercial or financial relationships that could be construed as a potential
conflict of interest.
Copyright © 2019 Arac, Grimbaldeston, Galli, Bliss and Steinberg. This is an
open-access article distributed under the terms of the Creative Commons Attribution
License (CC BY). The use, distribution or reproduction in other forums is permitted,
provided the original author(s) and the copyright owner(s) are credited and that the
original publication in this journal is cited, in accordance with accepted academic
practice. No use, distribution or reproduction is permitted which does not comply
with these terms.
Frontiers in Cellular Neuroscience | www.frontiersin.org 10 April 2019 | Volume 13 | Article 126
